Automating MS-based workflows to accelerate antibody-drug conjugate discovery
12 Jun 2026This case study describes how Merck streamlined antibody-drug conjugate (ADC) discovery by implementing the Genedata Biopharma Platform to automate mass spectrometry (MS)-based workflows. The solution integrates data from multiple analytical techniques, enabling consistent, real-time access to molecular and analytical information across global research sites.
By centralizing data and automating workflows, the platform eliminates manual data handling and reduces the risk of human error. It enables high-throughput processing of ADC samples, automatic calculation of key attributes such as drug-to-antibody ratio (DAR), and improved traceability across the discovery pipeline. This approach supports faster decision-making, improved data accessibility, and more efficient identification of promising ADC candidates.
Resource details:
- Resource type: Case study
- Page count: 2
- Read time: 3 mins


